+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

TCR-based Therapies Market by Target Indications, Target Antigens, Key Players and Key Geographies, Industry Trends and Global Forecasts, 2021-2030

  • ID: 5359102
  • Report
  • March 2021
  • Region: Global
  • 397 Pages
  • Roots Analysis

FEATURED COMPANIES

  • 6 Dimensions Capital
  • Bezos Expeditions
  • Franklin Templeton
  • Longwood Fund
  • Perspective Advisors
  • Tactiva Therapeutics

Overview

The inherent heterogeneity of cancer cells and the immunosuppressive properties of the tumor microenvironment make it difficult to design viable and effective therapeutics against oncological disorders. However, targeted cell-based immunotherapies have demonstrated significant potential in treating patients suffering from cancer. Modified T-cell receptor (TCR)-based therapies, an upcoming class of cell-based interventions, is a promising therapeutic modality. Their tumor-cell killing efficacy may be primarily attributed to the fact that they are pre-sensitized to cancer specific antigens; this enables such interventions to selectively target and eliminate tumor cells from the body of a host, with negligible treatment-related side effects. Ongoing and planned clinical research initiatives in this direction are driven by encouraging results achieved in past trials, which were mostly focused on various hematological cancers and solid tumors. Similar to other T-cell based interventions (such as CAR-T cells and TILs), TCR therapies are designed to target the underlying causes (or primary mediators) of a clinical condition. Additionally, this emerging class of biologics is believed to possess the potential to cater to unmet pharmacological needs across both oncological and non-oncological disorders, even those where small molecule drugs have proven to be inadequate. The contemporary TCR-based therapies market is characterized by a healthy and growing pipeline of close to 150 candidate therapies. More than 15 such therapies, including GSK3377794 (GlaxoSmithKline), IMCgp100 (Immunocore), YT-E001 (China Immunotech Biotechnology) and ADP-A2M4 (Adaptimmune Therapeutics), are in the advanced stages of development. 

Presently, more than 100 industry and non-industry players, across the globe claim to be engaged in the development and clinical evaluation of antigen sensitized TCR-based cell therapies. The growing interest in this field is reflected in the notable increase in partnership activity (close to 120 deals inked in the past decade alone; CAGR 29%), between various industry players and academic / research institutes. Mostly driven by the need for effective treatment options for cancer, the TCR-based therapy pipeline is expected to continue to steadily grow over the coming years. Moreover, clinical success is likely to draw in investments that will support ongoing and anticipated therapy development initiatives. Overall, we are led to believe that the global TCR-based therapies market is poised to witness significant growth in the foreseen future.

Scope of the Report

The “TCR-based Therapies Market by Target Indications (Bladder Cancer, Multiple Myeloma, Ovarian Cancer, Nasopharyngeal Carcinoma, Acute Myeloid Leukemia and Sarcoma), Target Antigens (NY-ESO-1, p53, WT-1 and EBV), Key Players (GlaxoSmithKline, Adaptimmune Therapeutics, Merck, Altor Bioscience, Juno Therapeutics and Takara Bio) and Key Geographies (North America, Europe and Asia Pacific) – Global Forecast 2021-2030” report features an extensive study of the current market landscape and future potential of TCR-based therapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry. 

Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape of TCR-based therapies with respect to type of developer (industry / non-industry), phase of development (preclinical, phase I, phase I/II and phase II,), therapeutic area (hematological cancer, solid tumor and others), popular target indications (lung cancer, melanoma, liver cancer, acute myeloid leukemia, ovarian cancer, multiple myeloma, sarcoma, head and neck cancer, bladder cancer, myelodysplastic syndrome, stomach cancer, pancreatic cancer, brain cancer, acute lymphoblastic leukemia, esophageal cancer and others), popular target antigen (NY-ESO-1, HBV, WT-1, HPV, MAGE-A4, KRAS, p53, PRAME, AFP, CD19, gp100, HPV E6, LAGE-1a, MART-1, Meso and others), source of T-cells (autologous / allogeneic), route of administration (intravenous, intratumor, intraperitoneal, intrapleural, intraventricular and others), dose frequency (single dose, multiple dose and split dose), target patient segment (children, adults and elderly patients), and type of therapy (monotherapy and combination therapy). Further, the chapter provides a list of the most active players (in terms of number of pipeline candidates) engaged in this domain. 
  • Detailed profiles of clinical products in developmental stages (phase I/II or above); each profile features an overview of the therapy, its mechanism of action,  clinical development plan, key clinical trial results and dosage information.
  • A detailed target antigen analysis, taking into consideration the number of TCR-based therapies that are being developed for a particular type of antigen by various industry stakeholders to identify potential targets.
  • An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2×2 analysis assessing the relative experience of KOLs shortlisted based on their contributions (in terms of involvement in various clinical studies) in this field, and a schematic world map representation, indicating the geographical location of eminent scientists / researchers engaged in the development of TCR-based therapies.
  • An overview of the focus therapeutic areas of drug developers, including an assessment of the opportunity (in terms of revenue generation potential from therapy sales) across oncological disease indications.
  • An analysis of the partnerships that have been established in the recent past, covering R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
  • An analysis of investments that have been made into companies which have proprietary, TCR-based products / technologies. The various type of funding instances reported in this domain include seed financing, venture capital financing, capital raised from IPOs and subsequent public offerings, grants, and debt financing.
  • A case study on manufacturing of cell therapy products, highlighting the key challenges associated with the production of such therapies. In addition, it features a detailed list of contract service providers and in-house manufacturers engaged in this market.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may adopt, in order to decide the price of a TCR-based therapy.
  • An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter, highlighting the yearly trend of tweets, most frequently talked about product candidates, popular disease indications, target antigens, as well as prolific authors and social media influencers.
  • A review of the key promotional strategies that have been adopted by developers of marketed T-cell therapies, namely KYMRIAH® and YESCARTA®.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for TCR-based therapies over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2021-2030. The report also includes likely sales forecasts of TCR-based therapies that are in the mid- to late stages of development. Additionally, it features market size projections for the overall TCR-based therapies market, wherein both the current and upcoming opportunity is segmented across [A] target indications (bladder cancer, multiple myeloma, ovarian cancer, nasopharyngeal carcinoma, acute myeloid leukemia and sarcoma), [B] target antigens (NY-ESO-1, p53, WT-1 and EBV), [C] key players (GlaxoSmithKline, Adaptimmune Therapeutics, Merck, Altor Bioscience, Juno Therapeutics and Takara Bio) and [D] key geographies (North America, Europe, Asia Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. 

The report features detailed transcripts of interviews held with the following individuals:

  • Tim Oldham (Chief Executive Officer, Cell Therapies)
  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Miguel Forte (Chief Operating Officer, TxCell)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • What are the prevalent R&D trends related to TCR-based therapies?
  • What are the key therapeutic areas for which TCR-based therapies are being / have been developed?
  • What are the challenges commonly faced by stakeholders engaged in this domain?
  • Who are the leading industry and non-industry players engaged in the development of TCR-based therapies?
  • Across which geographies, extensive research related to TCR-based therapies is being conducted?
  • Who are the key investors in this domain? 
  • Who are the key opinion leaders / experts engaged in this upcoming field of therapeutics?
  • What type of partnership models are commonly adopted by industry stakeholders? 
  • Across which regions is contract manufacturing support available for TCR-based therapies?
  • Which type of promotional strategies are likely to be adopted for TCR-based therapies that are approved or likely to be commercialized in the future?
  • Which factors are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments? 
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 6 Dimensions Capital
  • Bezos Expeditions
  • Franklin Templeton
  • Longwood Fund
  • Perspective Advisors
  • Tactiva Therapeutics

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapy
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1. Activation and Suppression Immunotherapy
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell-based Therapies
3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution of T-Cell Immunotherapies
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing Process of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.6.5.1. Retroviral Vectors
3.6.5.2. Lentiviral Vectors
3.6.5.3. Non-viral Transfection Methods
3.7. T-Cell Receptor (TCR)-based Cell Therapy
3.7.1. History of Development
3.7.2. Anatomical Layout of TCR
3.7.3. Development of TCR-based Therapies
3.7.4. Comparison of CAR-T and TCR-based Therapies
3.7.5. Challenges Associated with TCR-based Therapies
3.7.6. Key Challenges and Roadblocks
3.7.7. Concluding Remarks

4. EMERGING TRENDS ON SOCIAL MEDIA
4.1. Chapter Overview
4.2. TCR-based Therapies: Trends on Twitter
4.2.1. Historical Trend in Volume of Tweets
4.2.2. Trending Words / Phrases on Twitter
4.2.3. Most Popular Drugs on Twitter
4.2.4. Most Prolific Authors on Twitter
4.2.5. Most Popular Indications and Target Antigens

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. TCR-based Therapies: Overall Market Landscape
5.2.1. Analysis by Type of Developer
5.2.2. Analysis by Phase of Development
5.2.3. Analysis by Therapeutic Area
5.2.4. Analysis by Popular Target Indications
5.2.5. Analysis by Popular Target Antigen
5.2.6. Analysis by Source of T-Cells
5.2.7. Analysis by Route of Administration
5.2.8. Analysis by Dose Frequency
5.2.9. Analysis by Target Patient Segment
5.2.10. Analysis by Type of Therapy
5.2.11. Key Industry Players: Distribution by Number of Therapies in Pipeline
5.2.12. Key Non-Industry Players: Distribution by Number of Therapies in Pipeline

6. POPULAR TARGET ANTIGEN ANALYSIS
6.1. Chapter Overview
6.2. TCR-based Therapies: Analysis by Popular Target Antigens
6.2.1. Popular Target Antigens related to Hematological Malignancies
6.2.2. Popular Target Antigens related to Solid Tumors 

7. KEY OPINION LEADERS ANALYSIS
7.1. Chapter Overview
7.2. TCR-based Therapies: Key Opinion Leaders
7.2.1. TCR-based Therapies: Most Prominent Key Opinion Leaders

8. TCR-BASED THERAPY PROFILES
8.1. Chapter Overview
8.2. SPEAR T-Cells (Adaptimmune / GlaxoSmithKline)
8.2.1. Therapy Overview
8.2.1.1. Technology Platform
8.2.1.2. Letetresgene Autoleucel / GSK3377794 / NY-ESO SPEAR T-Cell
8.2.1.3. ADP-A2M10 (MAGE-A10) SPEAR T-Cell Therapy
8.2.1.4. ADP-A2AFP SPEAR T-Cell Therapy
8.2.1.5. ADP-A2M4 (MAGE-A4) SPEAR T-Cell Therapy
8.2.2. Current Development Status
8.2.3. Key Clinical Trial Results
8.2.4. Dosage Regimen and Manufacturing
8.3. IMCgp100 (Immunocore)
8.3.1. Therapy Overview
8.3.2. Current Development Status
8.3.3. Key Clinical Trial Results
8.3.4. Dosage Regimen and Manufacturing
8.4. ALT-801 (Altor BioScience)
8.4.1. Therapy Overview
8.4.1.1. History of Development
8.4.2. Current Development Status
8.4.3. Key Clinical Trial Results
8.4.4. Dosage Regimen
8.4.5. Patent Portfolio
8.5. JTCR016 (Juno Therapeutics)
8.5.1. Therapy Overview
8.5.2. Current Development Status
8.5.3. Key Clinical Trial Results
8.5.4. Dosage Regimen and Manufacturing
8.6. CMD-602 / WT1 TCR Therapy (Kuur Therapeutics)
8.6.1. Therapy Overview
8.6.1.1. History of Development
8.6.2. Current Development Status
8.6.3. Key Clinical Trial Results
8.6.4. Dosage Regimen and Manufacturing
8.7. TBI-1301 (Takara Bio)
8.7.1. Therapy Overview
8.7.2. Current Development Status
8.7.3. Key Clinical Trial Results
8.7.4. Dosage Regimen and Manufacturing
8.8. MDG1011 (Medigene)
8.8.1. Therapy Overview
8.8.2. Current Development Status
8.8.3. Key Clinical Trial Results
8.8.4. Dosage Regimen and Manufacturing

9. KEY THERAPEUTIC AREAS FOR TCR-BASED THERAPIES
9.1. Chapter Overview
9.2. Hematological Malignancies
9.2.1. Leukemia and Lymphoma
9.2.1.1. Leukemia: Introduction and Epidemiology
9.2.1.1.1. Acute Myeloid Leukemia (AML)
9.2.1.1.2. Chronic Myeloid Leukemia (CML)
9.2.1.1.3. Acute Lymphocytic Leukemia (ALL)
9.2.1.1.4. Chronic Lymphocytic Leukemia (CLL)
9.2.1.2. Lymphoma: Introduction and Epidemiology
9.2.1.3. Current Treatment Landscape
9.2.1.3.1. Targeted Therapies
9.2.1.4. TCR-based Therapies and Affiliated Research Landscape
9.2.1.4.1. TCR-based Therapies and Leukemia / Lymphoma
9.2.2. Multiple Myeloma
9.2.2.1. Introduction and Epidemiology
9.2.2.2. Current Treatment Landscape
9.2.2.3. TCR-based Therapies and Affiliated Research Landscape
9.3. Solid Tumors
9.3.1. Metastatic Melanoma
9.3.1.1. Introduction and Epidemiology
9.3.1.2. Current Treatment Landscape
9.3.1.3. TCR-based Therapies and Affiliated Research Landscape
9.3.2. Lung Cancer
9.3.2.1. Introduction and Epidemiology
9.3.2.2. Current Treatment Landscape
9.3.2.3. TCR-based Therapies and Affiliated Research Landscape
9.3.3. Pancreatic Cancer
9.3.3.1. Introduction and Epidemiology
9.3.3.2. Current Treatment Landscape
9.3.3.3. TCR-based Therapies and Affiliated Research Landscape
9.3.4. Liver Cancer
9.3.4.1. Current Treatment Landscape
9.3.4.2. TCR-based Therapies and Affiliated Research Landscape
9.3.5. Breast Cancer
9.3.5.1. Introduction and Epidemiology
9.3.5.2. Current Treatment Landscape
9.3.5.3. TCR-based Therapies and Affiliated Research Landscape
9.3.6. Ovarian Cancer
9.3.6.1. Introduction and Epidemiology
9.3.6.2. Current Treatment Landscape
9.3.6.3. TCR-based Therapies and Affiliated Research Landscape
9.3.7. Bladder Cancer
9.3.7.1. Introduction and Epidemiology
9.3.7.2. Current Treatment Landscape
9.3.7.3. TCR-based Therapies and Affiliated Research Landscape

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Types of Partnership Models
10.3. TCR-based Therapies Market: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Type of Partner
10.3.4. Most Popular Products
10.3.5. Most Active Industry Players: Analysis by Number of Partnerships
10.3.6. Most Active Non-Industry Players: Analysis by Number of Partnerships
10.3.7. Most Active Contract Manufacturers: Analysis by Number of Manufacturing Agreements
10.3.7. Regional Analysis
10.3.8. Intercontinental and Intracontinental Agreements

11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. TCR-based Therapies Market: Funding and Investment Analysis
11.3.1. Analysis by Year of Investment
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Most Active Players: Analysis by Number of Funding Instances
11.3.5. Analysis by Type of Investor
11.3.6. Most Active Investors: Analysis by Number of Funding Instances
11.3.7. Regional Analysis by Amount Invested

12. CASE STUDY: CELL THERAPY MANUFACTURING
12.1. Chapter Overview
12.2. Overview of Cell Therapy Manufacturing
12.3. Cell Therapy Manufacturing Models
12.3.1. Centralized Manufacturing Model
12.3.2. Decentralized Manufacturing Model
12.4. Scalability of Cell Therapy Manufacturing Processes
12.4.1. Scale-up
12.4.2. Scale-out
12.5. Types of Cell Therapy Manufacturers
12.6. Key Challenges Related to Manufacturing of Cell Therapies
12.7. Important Factors Affecting the Process of Cell Therapy Manufacturing
12.7.1. Characterization
12.7.2. Cost of Goods
12.8. Automation of Cell Therapy Manufacturing Processes
12.9. Cell Therapy Manufacturing Supply Chain
12.10. Companies with In-House Capabilities
12.11. Contract Manufacturers
12.12. Regulatory Landscape

13. COST PRICE ANALYSIS
13.1. Chapter Overview
13.2. Factors Contributing to the High Price of Cell / Gene Therapies
13.3. Pricing Models for T-Cell Therapies
13.3.1. Based on Associated Costs
13.3.2. Based on Availability of Competing Products
13.3.3. Based on Patient Segment
13.3.4. Based on the Opinions of Industry Experts
13.4. Reimbursement-related Considerations for T-Cell Therapies
13.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Cell Therapies

14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Scope and Limitations
14.3. Key Assumptions and Forecast Methodology
14.4. Overall TCR-based Therapies Market, 2021-2030
14.4.1. TCR-based Therapies Market: Distribution by Target Indication
14.4.2. TCR-based Therapies Market: Distribution by Target Antigen
14.4.3. TCR-based Therapies Market: Key Players
14.4.4. TCR-based Therapies Market: Distribution by Geography
14.4.5. Product-wise Sales Forecast
14.5.5.1. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck)
14.5.5.1.1. Target Patient Population
14.5.5.1.2. Sales Forecast (USD Million)
14.5.5.1.3. Net Present Value (USD Million)
14.5.5.1.4. Value Creation Analysis
14.6.5.2. IMCgp100 (Immunocore)
14.6.5.2.1. Target Patient Population
14.6.5.2.2. Sales Forecast (USD Million)
14.6.5.2.3. Net Present Value (USD Million)
14.6.5.2.4. Value Creation Analysis
14.7.5.3. YT-E001 (China Immunotech)
14.7.5.3.1. Target Patient Population
14.7.5.3.2. Sales Forecast (USD Million)
14.7.5.3.3. Net Present Value (USD Million)
14.7.5.3.4. Value Creation Analysis
14.7.5.4. TBI-1301 (Takara Bio)
14.7.5.4.1. Target Patient Population
14.7.5.4.2. Sales Forecast (USD Million)
14.7.5.4.3. Net Present Value (USD Million)
14.7.5.4.4. Value Creation Analysis
14.7.5.5. ALT 801 (Altor BioScience)
14.7.5.5.1. Target Patient Population
14.7.5.5.2. Sales Forecast (USD Million)
14.7.5.5.3. Net Present Value (USD Million)
14.7.5.5.4. Value Creation Analysis
14.7.5.6. JTCR016 (Juno Therapeutics)
14.7.5.6.1. Target Patient Population
14.7.5.6.2. Sales Forecast (USD Million)
14.7.5.6.3. Net Present Value (USD Million)
14.7.5.6.4. Value Creation Analysis
14.7.5.7. LioCyx (Lion TCR)
14.7.5.7.1. Target Patient Population
14.7.5.7.2. Sales Forecast (USD Million)
14.7.5.7.3. Net Present Value (USD Million)
14.7.5.7.4. Value Creation Analysis
14.7.5.8. LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology)
14.7.5.8.1. Target Patient Population
14.7.5.8.2. Sales Forecast (USD Million)
14.7.5.8.3. Net Present Value (USD Million)
14.7.5.8.4. Value Creation Analysis

15. PROMOTIONAL ANALYSIS
15.1. Chapter Overview
15.2. Channels Used for Promotional Campaigns
15.3. Summary of Product Website Analysis
15.4. Summary of Patient Support Services and Informative Downloads
15.5. KYMRIAH: Promotional Analysis
15.5.1. Drug Overview
15.5.2. Product Website Analysis
15.5.2.1. Messages for Healthcare Professionals
15.5.2.2. Messages for Patients
15.5.3. Patient Support Services and Informative Downloads
15.5.4. Other Promotional Activities
15.5.4.1. Presence in Conferences
15.6. YESCARTA: Promotional Analysis
15.6.1. Drug Overview
15.6.2. Product Website Analysis
15.6.2.1. Messages for Healthcare Professionals
15.6.2.3. Messages for Patients
15.6.3. Patient Support Services and Informative Downloads
15.6.4. Other Promotional Activities
15.6.4.1. Presence in Conferences

16. COMPANY PROFILES
16.1. Chapter Overview
16.2. Adaptimmune Therapeutics
16.3. Celgene
16.4. Immunocore
16.5. Kuur Therapeutics
16.6. Lion TCR
16.7. Kite Pharma (A Gilead Sciences Company)
16.8. Takara Bio
16.9. Ziopharm Oncology

17. CONCLUDING REMARKS

18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Cell Therapies
18.2.1. Interview Transcript: Tim Oldham, Chief Executive Officer
18.3. Kite Pharma
18.3.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
18.4. Lion TCR
18.4.1. Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
18.5. TxCell
18.5.1. Interview Transcript: Miguel Forte, Chief Operating Officer
18.6. Celyad
18.6.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncologys
18.7. Waisman Biomanufacturing
18.7.1. Interview Transcript: Brian Dattilo, Manager of Business Development

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Note: Product cover images may vary from those shown
  • 6 Dimensions Capital
  • Aditya Birla Capital
  • AbVitro
  • Acorn Pacific Ventures
  • Adage Capital Management
  • Adaptimmune Therapeutics
  • Adicet Bio
  • Agency for Science, Technology and Research (A*STAR)
  • Agent Capital
  • AgenTus Therapeutics
  • Aisling Capital
  • AJU IB Investment
  • Alaska Permanent Fund
  • Albert Einstein College of Medicine 
  • Alexandria Real Estate Equities
  • Alexandria Venture Investments
  • Alex's Lemonade Stand Foundation (ALSF)
  • Alpine Immune Sciences
  • Alta Partners
  • Altor BioScience 
  • Amgen
  • Amgen Ventures
  • Andera Partners
  • Andreessen Horowitz
  • ARCH Venture Partners
  • Arix Bioscience
  • ArrowMark Partners
  • Astellas Pharma
  • Astellas Venture Management
  • AstraZeneca
  • AT Impf
  • Athenex
  • Atlas Venture
  • Atreca
  • Autolus
  • Alumni Ventures Group
  • Baader Bank
  • Baxalta Ventures
  • Baxter Ventures
  • Baylor College of Medicine
  • Be The Match BioTherapies
  • Beijing 302 Hospital
  • Bellicum Pharmaceuticals 
  • Berlin Institute of Health
  • Bessemer Venture Partners
  • Bezos Expeditions
  • Bill & Melinda Gates Foundation 
  • Biomedical Catalyst 
  • BioNTech
  • bluebird bio
  • BNH Investment
  • Boehringer Ingelheim Venture Fund
  • Boxer Capital
  • Brace Pharma Capital
  • BrightEdge
  • BVCF 
  • California Institute for Regenerative Medicine (CIRM) 
  • California Institute of Technology
  • Cancer Prevention and Research Institute of Texas
  • Cancer Research UK
  • Captain T Cell
  • Cardiff University
  • Cartherics
  • Cell Design Labs
  • Cell and Gene Therapy Catapult
  • Cellular Biomedicine Group
  • Cellular Therapeutics
  • Changhai Hospital
  • Charité – Universitätsmedizin Berlin
  • China Immunotech (Beijing) Biotechnology
  • Cogent Biosciences
  • Cormorant Asset Management
  • Cowen
  • Cryoport
  • CRC for Cell Therapy Manufacturing
  • Curative Ventures
  • Cytovant Sciences
  • Dana-Farber Cancer Institute
  • Direct Selling Association of Malaysia (DSAM)
  • Ditch Plains Capital Management
  • DUMAC 
  • Duke-NUS Medical School
  • Earle A. Chiles Research Institute
  • EcoR1 Capital 
  • Editas Medicine
  • Edmond de Rothschild Investment Partners 
  • Efung Capital 
  • Ehime University
  • Eli Lilly
  • Eureka Therapeutics
  • Eutilex
  • F2 Ventures
  • F-Prime Capital
  • Fidelity Management & Research
  • First Affiliated Hospital of Jinan University
  • Fiverings 
  • Foresite Capital
  • Fosun Pharmaceutical
  • F-Prime Capital
  • Franklin Templeton
  • Fred Hutchinson Cancer Research Center
  • Fudan University
  • Fujian Provincial Cancer Hospital, Fujian Medical University
  • Fujita Health University
  • Gadeta
  • GE Healthcare
  • Genmab
  • Federal Ministry of Education and Research GigaGen
  • GlaxoSmithKline
  • Glycostem Therapeutics
  • GP Capital
  • Gritstone Oncology
  • Grower Venture Capital
  • Guangdong Xiangxue Precision Medical Technology
  • Guangzhou FineImmune Biotechnology
  • Guangzhou Institute of Respiratory Disease
  • GV
  • Haitong International Securities
  • Hebei Senlang Biotechnology
  • Hebei Yanda Lu Daopei Hospital
  • Helmholtz Zentrum München
  • Henan Provincial People's Hospital
  • HiFiBiO Therapeutics
  • Hillhouse Capital Group
  • dievini Hopp BioTech
  • Howard Hughes Medical Institute
  • Immatics
  • Immunocore
  • Imperial Innovations
  • Innovate UK
  • Intellia Therapeutics
  • Intrexon 
  • Invesco Perpetual
  • Invus
  • IRICoR
  • Japan Science and Technology Agency (JST)
  • Jebsen Capital
  • Jianxin Capital
  • Jonsson Comprehensive Cancer Center
  • Juno Therapeutics
  • JW Therapeutics
  • Karolinska Institutet
  • Kite Pharma
  • Kleiner Perkins
  • Kuur Therapeutics
  • Laurion Capital Management
  • Legend Biotech
  • Leiden University Medical Center 
  • Level One Partners
  • Life Technologies
  • Lilly Asia Ventures
  • Lion TCR
  • Longwood Fund
  • Loyola University Medical Center
  • Lucion Venture Capital Group 
  • Lyell Immunopharma
  • Malin
  • Massachusetts General Hospital 
  • MaSTherCell
  • Matrix Capital Management
  • Max Delbrück Centre for Molecular Medicine
  • MaxCyte
  • Medicxi Ventures
  • Medigene
  • MedImmune
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Merlin Nexus
  • Mie University
  • Miller Value Partners
  • Miltenyi Biotec
  • Mirae Asset Financial Group
  • Mission Bay Capital
  • MPM Capital
  • MSD Partners
  • Nagoya University
  • NantKwest
  • National Cancer Institute
  • National Heart, Lung, and Blood Institute
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • National Institute of Cancer Prevention and Research
  • National Institutes of Health
  • New Enterprise Associates
  • New Leaf Ventures
  • New York State Stem Cell Science Program (NYSTEM)
  • Nextech Invest
  • NIH Small Business Innovation Research (SBIR)
  • Noile-Immune Biotech
  • Novartis
  • Novartis Institutes for BioMedical Research (NIBR)
  • Novartis Venture Fund
  • Novo Nordisk
  • OCV Partners
  • OrbiMed
  • OrbiMed Advisors
  • Osage University Partners
  • Oslo University Hospital
  • Ospedale Pediatrico Bambino Gesù (OPBG)
  • Otsuka Pharmaceutical
  • Oxford BioMedica
  • PACT Pharma
  • Panacea Ventures
  • Parker Institute for Cancer Immunotherapy
  • Penn Medicine
  • Perceptive Bioscience Investments
  • Perspective Advisors
  • Phio Pharmaceuticals
  • Ping An Ventures
  • Pitango Venture Capital
  • Platinum Asset Management
  • Pontifax Venture Capital
  • Pontifax AgTech
  • POSCO Capital
  • Precigen
  • Precision BioSciences
  • Progenitor Cell Therapy
  • Providence Health & Services
  • QVT Financial
  • RA Capital Management
  • Redmile Group
  • RedoxTherapeis
  • Regeneron
  • Remeditex Ventures
  • Ridgeback Capital Management
  • Roche
  • Rock Springs Capital
  • Roswell Park Cancer Institute
  • RTW Investments
  • RXi Pharmaceuticals
  • Sabby Management
  • Samsara BioCapital
  • Sanofi-Genzyme BioVentures
  • SVB Leerink
  • Seattle Children’s Research Institute
  • Seattle Genetics
  • Second Affiliated Hospital of Guangzhou Medical University
  • Sectoral Asset Management
  • Shanghai Zhongshan Hospital
  • Shenzhen BinDeBio
  • Shenzhen Institute for Innovation and Translational Medicine
  • Shenzhen Second People's Hospital
  • Sirona Capital
  • Smilegate Investment
  • Square 1 Bank
  • Stage Cell Therapeutics 
  • Statcom 
  • Steam Athena Capital
  • Structured Immunity
  • Sun Yat-sen University
  • Syncona
  • Syno Capital
  • Tactiva Therapeutics
  • Takara Bio
  • TCRCure Biopharma
  • TCR2 Therapeutics
  • Tekla Capital Management
  • Leukemia and Lymphoma Society
  • The Netherlands Cancer Institute
  • The Texas Emerging Technology Fund
  • The University of California, Los Angeles (UCLA)
  • The University of Chicago 
  • The University of Texas Health Science Center
  • The University of Texas MD Anderson Cancer Center
  • The University of Tokyo Hospital
  • Thermo Fisher Scientific 
  • Tianjin Medical University
  • T-knife
  • Tmunity Therapeutics
  • Touchstone Innovations
  • Trout Capital 
  • TScan Therapeutics
  • Universal Cells
  • University College London
  • University Health Network
  • University Medical Center Utrecht
  • University of California San Francisco
  • University of Connecticut
  • University of Lausanne
  • University of Montreal
  • University of Oxford
  • University of Pennsylvania
  • University of Southern California
  • Utrecht Holdings
  • venBio
  • Venrock
  • Versant Ventures
  • VI Ventures
  • Vineti
  • Vivo Capital
  • Wellcome Trust
  • Wellington Management
  • Wellington Partners
  • Westlake Ventures 
  • Westlake Village BioPartners
  • White Rock Capital Partners 
  • Woodford Investment Management 
  • Wuhan Dangdai Science & Technology Industries 
  • WuXi AppTec
  • X-Body
  • Xiangxue Life Sciences
  • Xiangxue Pharmaceutical
  • Xinqiao Hospital 
  • Yeshiva University
  • Zelluna Immunotherapy
  • Zhejiang Huacheng Group
  • Zhejiang Huahai Pharmaceutical 
  • Zhejiang University
  • Zhujiang Hospital
  • Ziopharm Oncology
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...

Adroll
adroll